12:16 Oct 17, 2008 |
English to Portuguese translations [PRO] Science - Medical (general) / Virology/Pharmacology | |||||||
---|---|---|---|---|---|---|---|
|
| ||||||
| Selected response from: Sara Sousa Soares Local time: 18:27 | ||||||
Grading comment
|
Summary of answers provided | ||||
---|---|---|---|---|
4 +1 | fold changes |
| ||
4 | desdobramentos |
| ||
3 +1 | múltiplas/sucessivas alterações |
| ||
3 | multiplicação |
|
fold changes multiplicação Explanation: Diria assim... |
| |
Login to enter a peer comment (or grade) |
fold changes desdobramentos Explanation: É como vejo. |
| |
Login to enter a peer comment (or grade) |
fold changes fold changes Explanation: Encontrei este exemplo. Espero que ajude! «Os relatórios VircoType e PhenoSense incluiram cut-offs clínicos mais baixos e mais altos (Bacheler 2004). O cut-off clínico mais baixo é a fold-change (razão entre a IC50 do paciente e a IC50 de referência) na IC50 e indica uma resposta virológica ligeiramente reduzida. Uma fold-change acima do cut-off clínico mais alto indica resistência, e uma fold-change entre os dois cut-offs indica resistência parcial.» P.f. ver link... Reference: http://hivmedicine.aidsportugal.com/09_Resistance.php |
| |
Grading comment
| ||
Login to enter a peer comment (or grade) |
fold changes múltiplas/sucessivas alterações Explanation: Uma sugestão apenas. -------------------------------------------------- Note added at 3 hrs (2008-10-17 15:25:02 GMT) -------------------------------------------------- ************************************************* References pertaining to the term "fold changes" ************************************************* http://www.thebody.com/Forums/AIDS/Resistance/Archive/misc/Q... Forum Q&A Ask the Experts about Drug Resistance and Staying Undetectable Question: resistance testing Apr 23, 2007 I'm confused about resistance testing. When talking about phenotype testing, what is meant by "cut-offs" and "fold changes". Response from Dr. Sherer A genotype resistance test measures the sequence of virus, and thus results refer to specific mutations, M184V is a substitution of Methionine (Met) for Valine (Val) at the 184 locus. In contrast, results for a phenotype are given in relation to the difference, if any, between YOUR virus and 'wild-type' virus, i.e. a virus with no mutations. So we speak of one who has the M184V mutation, which confers reduced susceptibility to lamivudine, as having an '8-fold' reduction in susceptibility, i.e. it is 8x less susceptible with the mutation than another virus without the mutation. The big question is, what does this mean to you in the clinic? For this answer, we need to know what happens to patients who have an 8-fold reduction in susceptibility, i.e. at what clinical 'cut-off' of susceptibility is there a 20% loss of anti-viral activity (SOME resistance) and at what clinical cut-off is there an 80% loss of anti-viral activity (NEAR TOTAL resistance). These terms are confusing even to experienced clinicians, so I urge you to take these answers to your doctor and talk to him or her about them, in the context of your own test results. Hopefully that will lead to some clarity on the meaning of these terms. *************************************************** Note: I tried posting this information in the Reference Section but could not find it. |
| |
Login to enter a peer comment (or grade) |
Login or register (free and only takes a few minutes) to participate in this question.
You will also have access to many other tools and opportunities designed for those who have language-related jobs (or are passionate about them). Participation is free and the site has a strict confidentiality policy.